Please login to the form below

Not currently logged in
Email:
Password:

Tobi Podhaler

This page shows the latest Tobi Podhaler news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug

ranibizumab). Novartis has also won the cost-effectiveness watchdog's backing in 2013 for the Tobi Podhaler (tobramycin), a treatment for cystic fibrosis.

Latest news

  • NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

    The limited recommendation takes into account that the Tobi Podhaler and Colobreathe are dry powder versions of already available nebulised products. ... form. The Tobi Podhaler should only be used in cystic fibrosis patients for whom nebulised

  • NICE backs two cystic fibrosis treatments for NHS use NICE backs two cystic fibrosis treatments for NHS use

    NICE backs two cystic fibrosis treatments for NHS use. Novartis’ Tobi Podhaler and Forest’ s Colobreathe recommended at discounted price. ... Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS

  • NICE backs Novartis’ Tobi Podhaler in cystic fibrosis NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

    NICE backs Novartis’ Tobi Podhaler in cystic fibrosis. But draft guidance doesn't recommend Forest’ s Colobreathe. ... In addition, the Tobi Podhaler should only be available for patients unable to use nebulised colistimethate, or for whom nebulised

  • FDA panel backs Novartis' updated cystic fibrosis drug FDA panel backs Novartis' updated cystic fibrosis drug

    Novartis' current tobramycin product TOBI has been the standard of care of this infection in CF since it was launched in 1997, but is delivered using a nebuliser machine which is ... The new product is already approved in the EU and Canada, where it is

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler® and TOBI® solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics